Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Although uncommon, anti-HER2 antibodies can cause severe thrombocytopenia. Furthermore, if thrombocytopenia persists after treatment discontinuation and the administration of corticosteroids, exploring treatment options aligned with managing ITP is essential.
Authors
- Toru Kadono (ORCID: https://orcid.org/0000-0002-2898-4860)
- Hiroki Yukami (ORCID: https://orcid.org/0000-0001-7781-4609)
- Hiroki Nishikawa (ORCID: https://orcid.org/0000-0003-3489-2740)
- Elham Fakhrejahani
- Toshifumi Yamaguchi (ORCID: https://orcid.org/0000-0003-1399-1918)
- Dai Okemoto
- Mariko Yamaguchi
Institutions
- Breast Cancer Network Australia (AU)
- Osaka University Hospital (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Case Reports in Oncology
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1159/000540980
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00